Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

May 3, 2023

Investing in healthcare

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology. The technology helps bio drugs overcome intracellular barriers, making them more effective. Defence is excited about three upcoming clinical trials, expected to start by the end of the year, which will be important for the company's growth. Defence is also actively working to license their technology to other companies. The mRNA therapeutics market is projected to reach close to $130 billion by 2030, making the potential for Defence's growth promising.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

You might also like

Healthcare
Investor Alert - Defence Therapeutics: Developing Immune-related Therapies for Cancer Treatment

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles.

Healthcare
Defence Therapeutics: Developing Next Generation Therapies to Combat Cancer with Propietary ACCUM™ Technology

Cancer treatment along with other infectious diseases need clinical solutions and this company may have one. BTV interviews Defense Therapeutics to learn about their proprietary ACCUM™ technology and its proven ability to deliver treatment drugs to diseased cells.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!